- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Total 99 results
-
Novartis PharmaceuticalsRecruitingBRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid TumorJapan
-
Novartis PharmaceuticalsRecruitingRare Unresectable or Metastatic BRAF V600E Mutation-positive Solid TumorsUnited States
-
PfizerCompletedSolid Tumors Harboring a BRAF V600 MutationUnited States, France, Italy, Singapore, Australia, Spain, Switzerland, Canada, Belgium
-
ABM Therapeutics Shanghai Company LimitedRecruitingAdvanced Solid Tumor | BRAF V600 MutationChina
-
Deciphera Pharmaceuticals LLCRecruitingMelanoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor | Pancreatic Ductal Adenocarcinoma | BRAF Gene Mutation | RAS Mutation | NF1 Mutation | RAF Mutation | CRAF Gene MutationUnited States
-
Fore BiotherapeuticsActive, not recruitingAdvanced Unresectable Solid Tumors | BRAF-mutated TumorsUnited States
-
BioMed Valley Discoveries, IncTerminatedAdvanced Solid Tumor | MAP2K1 Gene Mutation | BRAF Gene Mutation | MEK Mutation | BRAF Gene Alteration | MEK Alteration | MAP2K1 Gene Alteration | MAP2K2 Gene Mutation | MAP2K2 Gene AlterationUnited States
-
Pierre Fabre MedicamentCompletedMelanoma | BRAF V600E Unresectable or Metastatic Melanoma | BRAF V600E Metastatic NSCLCChina
-
ABM Therapeutics CorporationTerminatedAdvanced Solid Tumor | BRAF V600 MutationUnited States
-
Pasithea Therapeutics Corp.RecruitingAdvanced Solid Tumors | RAS Mutation | NF1 Mutation | RAF MutationUnited States
-
Pierre Fabre MedicamentBiotrialActive, not recruitingMelanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 MutationFrance
-
Zhejiang UniversityRecruitingUnresectable or Metastatic Advanced Solid TumorsChina
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditionsUnited States
-
NKGen Biotech, Inc.Active, not recruitingMetastatic Cancer | Advanced Solid Tumor | Advanced Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer | Unresectable CarcinomaUnited States
-
Spago Nanomedical ABRecruitingSolid Tumor | Metastatic Cancer | Refractory Cancer | Locally Advanced Solid Tumor | Unresectable Solid Tumor | Recurrent Solid TumorAustralia
-
Pierre Fabre MedicamentBiotrialCompletedMelanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 MutationFrance
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Shanghai Xianxiang Medical Technology Co., Ltd.; Simcere ZaimingRecruitingLocally Advanced Unresectable or Metastatic Solid TumorUnited States, China
-
Txinno Bioscience Inc.RecruitingLocally Advanced (Unresectable) or Metastatic Solid TumorsKorea, Republic of
-
Innovent Biologics (Suzhou) Co. Ltd.Not yet recruitingLocally Advanced Unresectable or Metastatic Solid TumorsAustralia
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States
-
Astellas Pharma IncCompletedLocally Advanced (Unresectable) or Metastatic Solid Tumor MalignanciesJapan
-
BeBetter Med IncXiangya Hospital of Central South UniversityRecruitingAdvanced or Metastatic Solid Tumor | KRAS G12C MutationChina
-
Hangzhou Sumgen Biotech Co., Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsChina
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, China, Spain, Japan, United Kingdom
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, Canada
-
Relay Therapeutics, Inc.Active, not recruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Unresectable Solid Tumor | PIK3CA MutationUnited States
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsAustralia
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsAustralia
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyRecruitingMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, Canada, Spain
-
Genentech, Inc.CompletedMetastatic Melanoma, BRAF V600 Mutation PositiveKorea, Republic of, Russian Federation, Israel, United States
-
Daiichi Sankyo, Inc.PlexxikonTerminatedV600-mutated BRAF Unresectable Melanoma | V600-mutated BRAF Metastatic Melanoma | Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF InhibitorUnited States, Germany, France
-
Beijng Immunoah Pharma Tech Co., Ltd.RecruitingRecurrent or Metastatic, Advanced Solid TumorsChina
-
Novartis PharmaceuticalsCompletedAdvanced or Recurrent Solid TumorsJapan
-
Beijing Mabworks Biotech Co., Ltd.RecruitingHER2-positive Recurrent or Metastatic Malignant Solid TumorChina
-
ABM Therapeutics CorporationRecruitingAdvanced Solid Tumor | RAS Mutation | NF1 Mutation | RAF MutationUnited States
-
BayerRecruitingAdvanced or Recurrent Solid Tumor Harboring an NTRK Gene FusionJapan
-
Taiho Oncology, Inc.TerminatedAdvanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating MutationsUnited States, United Kingdom, Austria, France
-
Pierre Fabre MedicamentWithdrawnHepatic Impairment | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 MutationSpain, Czechia, Italy
-
National Cancer Center, JapanEisai Co., Ltd.Active, not recruitingAdvanced or Recurrent Solid Tumors | FGFR Gene AlterationsJapan
-
Incyte CorporationTerminatedAdvanced or Metastatic Solid Tumors | FGFR Mutations | FGFR TranslocationsUnited States
-
Black Diamond Therapeutics, Inc.RecruitingMelanoma | Colorectal Cancer | NSCLC | Solid Tumor | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Histiocytosis | Melanoma (Skin) | Recurrent Melanoma | Thyroid Carcinoma | Thyroid Cancer | Brain Metastases | Recurrent Histiocytic and Dendritic... and other conditionsUnited States
-
Frontier Medicines CorporationRecruitingColorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Unresectable Solid Tumor | KRAS G12C | Advanced Solid Tumors With KRAS G12C MutationsUnited States
-
Nested Therapeutics, IncRecruitingGlioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene MutationUnited States, Australia
-
Relay Therapeutics, Inc.RecruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Unresectable Solid Tumor | PIK3CA MutationUnited States, Spain, France, Italy
-
Blueprint Medicines CorporationCompletedGastrointestinal Stromal Tumors | GIST | Non-resectable Advanced Solid Tumors | Recurrent or Unresectable Central Nervous System (CNS) TumorsUnited States
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedAdvanced Solid Tumors With Alterations of FGFR1, 2 and or 3 | Squamous Lung Cancer With FGFR1 Amplification | Bladder Cancer With FGFR3 Mutation or Fusion | Advanced Solid Tumors With FGFR1 Amplication | Advanced Solid Tumors With FGFR2 Amplication | Advanced Solid Tumors With FGFR3 MutationFrance, Spain, Taiwan, Germany, Netherlands, Singapore, United States, Australia, Korea, Republic of, Thailand, Israel, Italy, Turkey, Austria
-
Peking UniversityRecruitingConditions or Focus of Study: B7-H3 Positive Relapsed/Advanced Malignant Solid TumorChina
-
Piramal Enterprises LimitedMelanoma Research Foundation Breakthrough ConsortiumSuspendedAdvanced or Inoperable Malignant Melanoma With BRAF MutationUnited States
-
BayerCompletedAdvanced or Recurrent Solid Tumor Harboring an NTRK Gene FusionJapan